NVO|Analyst Targets
NVO|Company Info
NVO|Earnings Snapshot
EPS
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q1'26 | $6.96 | - | - |
| Q3'25 | $4.24 | $4.50 | +6.0% |
| Q2'25 | $6.00 | $5.96 | -0.7% |
| Q1'25 | $6.07 | $6.53 | +7.5% |
| Q4'24 | $6.12 | $6.34 | +3.7% |
Revenue
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q1'26 | $71.6B | - | - |
| Q3'25 | - | $75.0B | - |
| Q2'25 | - | $76.9B | - |
| Q1'25 | - | $78.1B | - |
| Q4'24 | - | $85.7B | - |
NVO|Monthly Returns
Market Data
NVO Stock Snapshot
- Market cap
- 167.96B
- P/E ratio
- 9.8
- Day range
- $37.70 – $38.42
- News sentiment
- 38/100 · Bearish
- Analyst target
- $45.25 (+19.1%)
- Consensus
- Hold · 36 analysts
Price action on NVO is defensive - rallies are being sold rather than extended. The stock is liquid enough that positioning changes get absorbed without distorting the trend.
Behaviour On Record
What NVO's own history says about today's numbers
- Realized volatility (21d)
- 35.2% 77th pct
- Below its peak
- -74.3%
- vs 200-day average
- -16.0%
- Up days (1y)
- 45%
Novo Nordisk A/S is currently running 35.2% annualised volatility over the last 21 sessions. Measured against NVO's own 13 years of daily returns rather than a market-wide average, that is the 77th percentile — elevated for this stock, against a typical reading of 26.1%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.
NVO is trading -74.3% below its running peak. Across 12 full years on file, its median worst-drawdown-in-a-year was -18.0%, and the deepest was -50.4% in 2025. The current drawdown is already deeper than this stock's typical annual low point, which puts it in the part of its range where past recoveries began — and where past declines also continued.
Price sits -16.0% from its 200-day moving average. Against every other day in its history, that gap ranks at the 15th percentile — a narrower gap than it typically runs. Over the past year NVO closed higher on 45% of sessions, and it is currently 3 sessions into a falling streak.
On October specifically: over 14 years of records, NVO finished the month higher 6 of 14 times, with a median return of -1.6% and an average of -1.3%. Its strongest month historically has been April at +3.5% on average, its weakest September at -3.7%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.
Overnight risk is measurable too: NVO has opened more than 2% away from the prior close in 249 of 3,268 sessions (7.6% of the time), with the largest gaps running +6.5% and -14.0%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.
All figures computed from 3,269 daily closes between 2013-10-15 and 2026-10-14, split-adjusted, recomputed daily. Percentiles are against NVO's own 13-year history, not a peer group or index.
Sector Rotation
Is money rotating into or out of NVO's sector?
Novo Nordisk A/S sits in the Health Care sector, currently ranked 2nd of 12 GICS sectors by relative-strength rotation score (leading). Within its narrower Pharmaceuticals industry group, NVO ranks 12th of 15 tracked industries, improving.
- Sector rank
- #2 of 12
- Sector state
- Leading
- Sector rotation score
- 82
- Industry rank
- #12 of 15
Analyst Rating Changes
Are analysts turning bullish or bearish on NVO?
BMO Capital most recently reiterated its rating on Novo Nordisk A/S to Market Perform on Oct 12, 2026 with a price target of $40 (from $47). Over the last 90 days, coverage has run 0 upgrades against 1 downgrade, a net bearish lean.
- Latest action
- BMO Capital — Market Perform
- 90-day upgrades
- 0
- 90-day downgrades
- 1
- Net rating momentum
- -1
Peers & ETF holders
NVO peers & ETF holders
Drug Manufacturers - GeneralMarket cap · today
News Sentiment Analysis
Sentiment gathered from recent headlines
Recent News Coverage
Most recent articles, ranked by recency (click to expand).
Technical Analysis
Real-time indicators across multiple timeframes
| Manager | Trend | Shares Held | % of Co. | Position Value | Filed |
|---|---|---|---|---|---|
| Loomis Sayles & Co L P | ▲ Buy | 18,594,352 | 0.42% | $891.41M | 2026-08-14 |
| Morgan Stanley | ▲ Buy | 11,659,869 | 0.26% | $558.97M | 2026-08-13 |
| Bank of America Corp | ▲ Buy | 11,176,712 | 0.25% | $535.81M | 2026-08-14 |
| Goldman Sachs Group Inc | ▲ Buy | 9,180,490 | 0.21% | $440.11M | 2026-08-14 |
| Fisher Asset Management, LLC | ▼ Sell | 8,324,948 | 0.19% | $399.10M | 2026-08-04 |
| Capital World Investors | ▼ Sell | 5,205,926 | 0.12% | $249.61M | 2026-08-12 |
| Susquehanna International Group, LLP | ▼ Sell | 4,815,576 | 0.11% | $230.86M | 2026-08-14 |
| Wells Fargo & Company | ▲ Buy | 4,657,642 | 0.11% | $223.29M | 2026-08-14 |
| BlackRock, Inc. | ▲ Buy | 3,861,182 | 0.09% | $185.11M | 2026-08-07 |
| Northern Trust Corp | ▲ Buy | 3,693,198 | 0.08% | $177.05M | 2026-08-13 |
| Renaissance Technologies LLC | ▼ Sell | 3,032,421 | 0.07% | $145.37M | 2026-08-13 |
| Farallon Capital Management LLC | ▲ Buy | 2,619,000 | 0.06% | $125.55M | 2026-08-14 |
| FMR LLC (Fidelity) | ▲ Buy | 2,306,393 | 0.05% | $110.57M | 2026-08-13 |
| Millennium Management LLC | ▲ Buy | 2,035,939 | 0.05% | $97.60M | 2026-08-14 |
| Marshall Wace, LLP | ▼ Sell | 1,707,104 | 0.04% | $81.84M | 2026-08-13 |
| Maverick Capital Ltd | ▼ Sell | 1,653,872 | 0.04% | $79.29M | 2026-08-14 |
| JPMorgan Chase & Co | ▼ Sell | 1,612,426 | 0.04% | $77.94M | 2026-08-12 |
| Citadel Advisors LLC | ▼ Sell | 1,366,275 | 0.03% | $65.50M | 2026-09-02 |
| Balyasny Asset Management L.P. | ▲ Buy | 1,109,982 | 0.03% | $53.21M | 2026-08-14 |
| Citigroup Inc | ▼ Sell | 1,006,032 | 0.02% | $48.23M | 2026-08-03 |
| Adage Capital Partners GP, L.L.C. | ▲ Buy | 877,635 | 0.02% | $42.07M | 2026-08-14 |
| D. E. Shaw & Co., Inc. | ▼ Sell | 697,567 | 0.02% | $33.44M | 2026-08-14 |
| Invesco Ltd. | ▼ Sell | 686,121 | 0.02% | $32.89M | 2026-08-14 |
| AQR Capital Management LLC | ▲ Buy | 324,149 | 0.01% | $15.54M | 2026-08-14 |
| ExodusPoint Capital Management, LP | ▼ Sell | 170,652 | 0.00% | $8.18M | 2026-08-14 |
| Member | Chamber | State | Type | Amount | Traded | Filed |
|---|---|---|---|---|---|---|
| Kevin Hern | House | OK01 | ▼ Sell | $1K - $15K | 2026-09-10 | 2026-09-25 |
| Kevin Hern | House | OK01 | ▼ Sell | $1K - $15K | 2026-08-31 | 2026-09-25 |
| Scott Scott Franklin | House | FL18 | ▲ Buy | $1K - $15K | 2026-08-26 | 2026-09-17 |
| Alan Armstrong | Senate | OK | ▲ Buy | $15K - $50K | 2026-03-30 | 2026-07-21 |
| Lisa McClain | House | MI09 | ▼ Sell | $1K - $15K | 2025-10-31 | 2025-11-21 |
| Lisa McClain | House | MI09 | ▼ Sell | $1K - $15K | 2025-10-30 | 2025-11-21 |
| Lisa McClain | House | MI09 | ▲ Buy | $1K - $15K | 2025-10-30 | 2025-11-21 |
| Marjorie Taylor Greene | House | GA14 | ▲ Buy | $1K - $15K | 2025-10-15 | 2025-10-20 |
| Lisa McClain | House | MI09 | ▲ Buy | $1K - $15K | 2025-09-11 | 2025-10-22 |
| Marjorie Taylor Greene | House | GA14 | ▲ Buy | $1K - $15K | 2025-08-28 | 2025-08-29 |
| Marjorie Taylor Greene | House | GA14 | ▲ Buy | $15K - $50K | 2025-08-19 | 2025-08-20 |
| Scott Scott Franklin | House | FL18 | ▲ Buy | $15K - $50K | 2025-08-04 | 2025-08-14 |
| Lisa McClain | House | MI09 | ▼ Sell | $1K - $15K | 2025-08-04 | 2025-09-12 |
| Lisa McClain | House | MI09 | ▼ Sell | $1K - $15K | 2025-07-10 | 2025-08-13 |
| Lisa McClain | House | MI09 | ▲ Buy | $1K - $15K | 2025-06-09 | 2025-08-13 |
| Laurel Lee | House | FL15 | ▼ Sell | $1K - $15K | 2025-05-08 | 2025-06-22 |
| Scott Scott Franklin | House | FL18 | ▲ Buy | $1K - $15K | 2025-03-27 | 2025-04-11 |
| Byron Donalds | House | FL19 | ▼ Sell | $1K - $15K | 2025-03-20 | 2025-04-14 |
| Valerie Hoyle | House | OR04 | ▲ Buy | $1K - $15K | 2024-10-29 | 2025-09-12 |
| Tommy Tuberville | Senate | AL | ▼ Sell | $15K - $50K | 2024-01-19 | 2024-02-14 |
| Shelley Moore Capito | Senate | WV | ▼ Sell | $1K - $15K | 2019-03-11 | 2019-04-17 |
| Shelley Moore Capito | Senate | WV | ▲ Buy | $1K - $15K | 2017-09-08 | 2017-10-06 |